AXA WF Framlington Health - Under Review

FUND RESEARCH UPDATE: Fund rating moved to Under Review

Ruli Viljoen 31 July, 2014 | 3:25PM
Facebook Twitter LinkedIn

Following the announcement by AXA Framlington that Gemma Game, manager of the AXA WF Framlington Health fund, will be leaving the firm on 28th October 2014, we have placed the fund’s Morningstar OBSR Analyst Rating™ Under Review. The fund previously held a Bronze rating. Gemma Game has been the key driver of the fund’s success in recent years and we view her departure as a loss to the fund. In the interim period prior to her replacement, Mark Hargraves, Head of Continental Europe, will assume responsibility for the fund, and will be assisted by biotechnology fund manager Linden Thomson. We will review the fund in due course once a permanent replacement has been appointed.

See the latest Morningstar OBSR fund rating news here.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
AXAWF Longevity Economy A Cap USD290.24 USD0.47Rating

About Author

Ruli Viljoen

Ruli Viljoen  is Head of Manager Selection, Morningstar UK

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures